Trial Outcomes & Findings for Lidocaine as an Endotracheal Tube (ETT) Cuff Media (NCT NCT03343080)

NCT ID: NCT03343080

Last Updated: 2019-09-27

Results Overview

Total amount of Propofol dose used as measured in total milligrams.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

32 participants

Primary outcome timeframe

baseline through extubation

Results posted on

2019-09-27

Participant Flow

Participant milestones

Participant milestones
Measure
Buffered Lidocaine
1.8% lidocaine plus 0.76% sodium bicarbonate: At the time of intubation, the endotracheal tube cuff will be inflated with a solution containing 1.8% lidocaine plus 0.76% sodium bicarbonate until loss of air leak at a positive pressure of 20 cm of water
Air Only
Air: At the time of intubation, the endotracheal tube cuff will be inflated with air until loss of air leak at a positive pressure of 20 cm of water. The air will remain in situ through the duration of cardiac surgery, transportation to the intensive care unit, and continued to the time of extubation.
Overall Study
STARTED
14
18
Overall Study
COMPLETED
14
18
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Buffered Lidocaine
n=14 Participants
1.8% lidocaine plus 0.76% sodium bicarbonate: At the time of intubation, the endotracheal tube cuff will be inflated with a solution containing 1.8% lidocaine plus 0.76% sodium bicarbonate until loss of air leak at a positive pressure of 20 cm of water
Air Only
n=18 Participants
Air: At the time of intubation, the endotracheal tube cuff will be inflated with air until loss of air leak at a positive pressure of 20 cm of water. The air will remain in situ through the duration of cardiac surgery, transportation to the intensive care unit, and continued to the time of extubation.
Total
n=32 Participants
Total of all reporting groups
Age, Continuous
62.1 years
STANDARD_DEVIATION 14.9 • n=14 Participants
59.4 years
STANDARD_DEVIATION 16.6 • n=18 Participants
60.7 years
STANDARD_DEVIATION 15.8 • n=32 Participants
Sex: Female, Male
Female
3 Participants
n=14 Participants
7 Participants
n=18 Participants
10 Participants
n=32 Participants
Sex: Female, Male
Male
11 Participants
n=14 Participants
11 Participants
n=18 Participants
22 Participants
n=32 Participants
Race and Ethnicity Not Collected
0 Participants
Race and Ethnicity were not collected from any participant.
Region of Enrollment
United States
14 participants
n=14 Participants
18 participants
n=18 Participants
32 participants
n=32 Participants

PRIMARY outcome

Timeframe: baseline through extubation

Population: Only 10 subjects in the buffered lidocaine arm and 13 subjects in the air only arm received Propofol for sedation. The remaining subjects received other sedation drugs per physician discretion.

Total amount of Propofol dose used as measured in total milligrams.

Outcome measures

Outcome measures
Measure
Buffered Lidocaine
n=10 Participants
1.8% lidocaine plus 0.76% sodium bicarbonate: At the time of intubation, the endotracheal tube cuff will be inflated with a solution containing 1.8% lidocaine plus 0.76% sodium bicarbonate until loss of air leak at a positive pressure of 20 cm of water
Air Only
n=13 Participants
Air: At the time of intubation, the endotracheal tube cuff will be inflated with air until loss of air leak at a positive pressure of 20 cm of water. The air will remain in situ through the duration of cardiac surgery, transportation to the intensive care unit, and continued to the time of extubation.
Total Sedation Requirements
325 milligrams
Standard Deviation 248
1158 milligrams
Standard Deviation 1426

SECONDARY outcome

Timeframe: baseline through extubation

Total amount of time that the participant is intubated as measured in minutes.

Outcome measures

Outcome measures
Measure
Buffered Lidocaine
n=14 Participants
1.8% lidocaine plus 0.76% sodium bicarbonate: At the time of intubation, the endotracheal tube cuff will be inflated with a solution containing 1.8% lidocaine plus 0.76% sodium bicarbonate until loss of air leak at a positive pressure of 20 cm of water
Air Only
n=18 Participants
Air: At the time of intubation, the endotracheal tube cuff will be inflated with air until loss of air leak at a positive pressure of 20 cm of water. The air will remain in situ through the duration of cardiac surgery, transportation to the intensive care unit, and continued to the time of extubation.
Total Duration of Mechanical Ventilation
499 minutes
Interval 440.0 to 613.0
529 minutes
Interval 380.0 to 700.0

SECONDARY outcome

Timeframe: 4 hours post-extubation

The Richmond Agitation-Sedation Scale (RASS) is a medical scale used to measure the agitation or sedation level of a patient.. It is a 10-point scale comprised of four levels of agitation (+1 to +4), one level defining a calm and alert state (0) and five levels of sedation (-1 to -5). The higher the positive number (+) the more agitated or combative a patient is and the higher the negative number (-) the deeper the sedation of the patient.

Outcome measures

Outcome measures
Measure
Buffered Lidocaine
n=14 Participants
1.8% lidocaine plus 0.76% sodium bicarbonate: At the time of intubation, the endotracheal tube cuff will be inflated with a solution containing 1.8% lidocaine plus 0.76% sodium bicarbonate until loss of air leak at a positive pressure of 20 cm of water
Air Only
n=18 Participants
Air: At the time of intubation, the endotracheal tube cuff will be inflated with air until loss of air leak at a positive pressure of 20 cm of water. The air will remain in situ through the duration of cardiac surgery, transportation to the intensive care unit, and continued to the time of extubation.
Richmond Agitation-Sedation Score (RASS)
-0.2 score on a scale
Standard Deviation 0.4
-0.4 score on a scale
Standard Deviation 0.5

Adverse Events

Buffered Lidocaine

Serious events: 0 serious events
Other events: 14 other events
Deaths: 0 deaths

Air Only

Serious events: 0 serious events
Other events: 18 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Buffered Lidocaine
n=14 participants at risk
1.8% lidocaine plus 0.76% sodium bicarbonate: At the time of intubation, the endotracheal tube cuff will be inflated with a solution containing 1.8% lidocaine plus 0.76% sodium bicarbonate until loss of air leak at a positive pressure of 20 cm of water
Air Only
n=18 participants at risk
Air: At the time of intubation, the endotracheal tube cuff will be inflated with air until loss of air leak at a positive pressure of 20 cm of water. The air will remain in situ through the duration of cardiac surgery, transportation to the intensive care unit, and continued to the time of extubation.
General disorders
Agitation or restlessness
0.00%
0/14 • Adverse events were recorded from baseline to 4 hours post extubation for each subject.
5.6%
1/18 • Number of events 1 • Adverse events were recorded from baseline to 4 hours post extubation for each subject.
General disorders
Difficulty swallowing
7.1%
1/14 • Number of events 1 • Adverse events were recorded from baseline to 4 hours post extubation for each subject.
11.1%
2/18 • Number of events 2 • Adverse events were recorded from baseline to 4 hours post extubation for each subject.
General disorders
Hoarseness present
71.4%
10/14 • Number of events 10 • Adverse events were recorded from baseline to 4 hours post extubation for each subject.
83.3%
15/18 • Number of events 15 • Adverse events were recorded from baseline to 4 hours post extubation for each subject.
General disorders
Cough
28.6%
4/14 • Number of events 4 • Adverse events were recorded from baseline to 4 hours post extubation for each subject.
38.9%
7/18 • Number of events 7 • Adverse events were recorded from baseline to 4 hours post extubation for each subject.

Additional Information

Dr. Troy Seelhammer

Mayo Clinic

Phone: 507-255-6051

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place